Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes

This publication has 35 references indexed in Scilit:

• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
  Nature Medicine, 2003
• [2-Sulfo-9-fluorenylmethoxycarbonyl]3–exendin-4—a long-acting glucose-lowering prodrug
  Biochemical and Biophysical Research Communications, 2003
• Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
  Pflügers Archiv - European Journal of Physiology, 1998
• Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
  Diabetologia, 1998
• Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
  Journal of Clinical Investigation, 1998
• Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides
  Regulatory Peptides, 1995
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients
  Diabetologia, 1993
• Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
  Digestive Diseases and Sciences, 1993
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
  Journal of Clinical Investigation, 1993
• Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA
  Nature, 1993